Neurocrine Biosciences to Present at the Cowen 41st Annual Health Care Conference

Rhea-AI Summary

Neurocrine Biosciences (Nasdaq: NBIX) will present at the Cowen 41st Annual Health Care Conference on March 2, 2021, at 1:30 p.m. Eastern Time. CEO Kevin Gorman is set to deliver the presentation. A live webcast will be available on Neurocrine's website, with a replay accessible one hour after the event and archived for approximately one month. Neurocrine focuses on developing treatments for neurological and psychiatric disorders, with an array of FDA-approved therapies for conditions like tardive dyskinesia and Parkinson's disease.

News Market Reaction – NBIX

+1.86%

+1.86% Session move

In the trading session that priced this news, NBIX gained 1.86%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Feb. 23, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Cowen 41^st Annual Health Care Conference at 1:30 p.m. Eastern Time on Tuesday Mar. 2, 2021. Kevin Gorman, Chief Executive Officer, will present at the conference.

The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, Neurocrine Biosciences has specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)

View original content to download multimedia:http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-cowen-41st-annual-health-care-conference-301233900.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

When is Neurocrine Biosciences presenting at the Cowen 41st Annual Health Care Conference?

Neurocrine Biosciences will present on March 2, 2021, at 1:30 p.m. Eastern Time.

Who will present on behalf of Neurocrine Biosciences at the conference?

CEO Kevin Gorman will present at the Cowen 41st Annual Health Care Conference.

How can I access the live webcast of Neurocrine's presentation?

The live webcast can be accessed on Neurocrine's website under the Investors section.

Is there a replay available for Neurocrine's conference presentation?

Yes, a replay will be available approximately one hour after the presentation and archived for about one month.

What is the focus of Neurocrine Biosciences?

Neurocrine Biosciences focuses on developing treatments for serious neurological and psychiatric disorders.